Tech Company Financing Transactions
MicuRx Pharmaceuticals Funding Round
MicuRx Pharmaceuticals, operating out of Foster City, received $10 million from Morningside Group.
Transaction Overview
Company Name
Announced On
6/25/2007
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series A
Investors
Morningside Group (George Chang)
Proceeds Purpose
Mike Gordeev, Ph.D., executive vice
president and chief scientific officer of MicuRx said, "We are aggressively
moving forward to implement our proprietary approach and expect to identify
our first development candidates with significantly improved therapeutic
potential on an accelerated timeline."
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
950 Tower Ln. 390
Foster City, CA 94404
USA
Foster City, CA 94404
USA
Phone
Website
Email Address
Overview
MicuRx is discovering and developing next-generation antibacterial andantifungal products. By making specific modifications to validatedantibiotics, MicuRx intends to improve overall pharmacological propertiesof antimicrobial drugs in order to overcome antibiotic resistance.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Zhengyu Yuan
Chief Financial Officer
Zhiyue Li
Chief Marketing Officer
Barry Hafkin
Chief Scientific Officer
Michael Gordeev
Browse more venture capital transactions:
Prev: 6/25/2007: Palo Alto Networks venture capital transaction
Next: 6/25/2007: Rivermine Software venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs